LLY ELI LILLY & Co

CIK 0000059478 50 ready 8-Ks latest August 5, 2026, 7:05 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 5, 2026, 7:05 AM ET

Top materiality 0.90

Event mix earnings ×23 · leadership ×10 · debt ×8

Sentiment 24 pos · 0 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for LLY

Highest-materiality recent filing

Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance

August 8, 2023, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).
FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.

Read filing →

August 5, 2026, 7:05 AM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance

Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).
May 20, 2026, 4:30 PM ET debt materiality 0.80 neutral item 8.01 item 9.01

Lilly completes $9B multi-tranche debt offering tied to Centessa acquisition

Completed $9.0B aggregate principal debt offering across eight tranches of floating and fixed-rate notes due 2026-2066.
April 30, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo

Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
February 4, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B

Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.
October 30, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand

Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.
August 7, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance

Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.
May 1, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance

Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.
February 12, 2025, 6:59 PM ET debt materiality 0.75 neutral item 8.01 item 9.01

Eli Lilly issues $6.5B of notes across 6 tranches; net proceeds ~$6.46B

Issues $1B 4.550% notes due 2028, $1.25B 4.750% notes due 2030, $1B 4.900% notes due 2032.
February 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue

Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).
January 14, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B

2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.
October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B

Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.
September 9, 2024, 7:59 PM ET leadership materiality 0.75 positive item 5.02 item 9.01 ◈ executive_change

Lilly appoints Lucas Montarce as EVP and CFO, effective Sept 9, 2024

Lucas Montarce, 47, promoted from president of Spain/Portugal/Greece hub to CFO, effective immediately.
August 8, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B

Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).
July 10, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change ×2

Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15

Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.
June 5, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change

Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024

Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.
April 30, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B

Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.
February 9, 2024, 6:59 PM ET debt materiality 0.60 neutral item 8.01 item 9.01

Lilly issues $6.5B in notes across five tranches with coupons 4.5%-5.1%

Issued $1B 4.5% Notes due 2027, $1B 4.5% Notes due 2029, $1.5B 4.7% Notes due 2034.
February 6, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued

Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).
November 2, 2023, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q3 revenue up 37% to $9.5B; reported EPS loss $0.06 on $3.29 IPR&D charges, non-GAAP EPS $0.10

Revenue $9,498.6M (+37% YoY) driven by Mounjaro, Verzenio, and $1.42B from olanzapine rights sale.
August 8, 2023, 7:59 PM ET earnings materiality 0.90 positive item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance

Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).
April 27, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q1 revenue $6.96B (-11%); EPS $1.49 (-29%); core biz ex-COVID +10%; guidance raised

Revenue $6.96B, down 11% YoY; ex-COVID-19 antibodies up 10% on Mounjaro, Trulicity, Verzenio, Jardiance.
February 2, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10

Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).
December 13, 2022, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches

2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.
November 1, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Lilly Q3 2022: revenue up 2% to $6.94B, reported EPS $1.61 (+32%), Mounjaro launch strong

Revenue $6,941.6M (+2% reported, +7% constant currency); total volume +14%.
August 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%

Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.
April 28, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly Q1 2022 revenue up 15% to $7.81B; reported EPS $2.10, non-GAAP $2.62; raises guidance

Revenue $7.81B (+15% YoY); volume growth 20%; core product sales up 13 ppt.
February 3, 2022, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed

Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).
December 15, 2021, 6:59 PM ET other material materiality 0.70 positive item 2.02 item 9.01

Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15

2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.
October 26, 2021, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab

Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).
August 17, 2021, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

Lilly restructures leadership; Zulueta retiring, Yuffa to lead International, new Neuroscience & Immunology units

Alfonso Zulueta, President of Lilly International, to retire effective Dec 26, 2021; succeeded by Ilya Yuffa.
August 3, 2021, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance

Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).

Executive changes

Departed

Karen Walker

Director

LLY · ELI LILLY & Co

Effective: 2024-12-31
Filed: November 19, 2024, 6:59 PM ET

Karen Walker notified the Board of her resignation from the Board effective December 31, 2024.

Appointed

Lucas Montarce

executive vice president and chief financial officer

LLY · ELI LILLY & Co

Effective: 2024-09-09
Filed: September 9, 2024, 7:59 PM ET

elected Lucas Montarce, age 47, as executive vice president and chief financial officer

Departed

Marschall S. Runge

Director

LLY · ELI LILLY & Co

Effective: 2024-08-31
Filed: August 16, 2024, 7:59 PM ET

On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024.

Appointed (interim)

Gordon Brooks

interim chief financial officer

LLY · ELI LILLY & Co

Effective: 2024-07-15
Filed: July 10, 2024, 7:59 PM ET

Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.

Departed

Anat Ashkenazi

executive vice president and chief financial officer

LLY · ELI LILLY & Co

Successor: Gordon Brooks
Filed: July 10, 2024, 7:59 PM ET

On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

Departed

Anat Ashkenazi

Executive Vice President and Chief Financial Officer

LLY · ELI LILLY & Co

Filed: June 5, 2024, 7:59 PM ET

Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.

Appointed

Dr. Mary Lynne Hedley

Director

LLY · ELI LILLY & Co

Effective: 2022-05-15
Filed: May 6, 2022, 7:59 PM ET

On May 2, 2022, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Dr. Mary Lynne Hedley as a new member of the class of 2025, effective May 15, 2022.

Departed

Carolyn R. Bertozzi

Director

LLY · ELI LILLY & Co

Effective: 2021-08-23
Filed: August 25, 2021, 7:59 PM ET

In connection with the Company’s entry into the collaboration and licensing agreement, Carolyn R. Bertozzi, academic founder of Lycia, resigned from the Company’s Board of Directors, effective August 23, 2021.

Departed

Alfonso Zulueta

Senior Vice President and President, Lilly International

LLY · ELI LILLY & Co

Effective: 2021-12-26
Filed: August 17, 2021, 7:59 PM ET

On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021.

Earnings & guidance

2026-Q1 EPS reported $8.26 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

24 positive 0 negative 26 neutral

source · LLY on sec.gov